Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, MD. Details regarding the Be Biopharma presentation at the conference are as follows: Title: CRISPR/Cas9-based precision B cell gene engineering coupled with artificial intelligence-guided protein desig